Less but better: Cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

Acta Diabetologica

Volumn 51, Issue 4, 2014, Pages 625-632

  Fendler, Wojciech ^a   Rizzo, Manfredi ^b   Borowiec, Maciej ^a   Malachowska, Beata ^a   Antosik, Karolina ^a   Szadkowska, Agnieszka ^a   Banach, Maciej ^a   Urbanska Kosinska, Malgorzata ^c   Szopa, Magdalena ^d   Malecki, Maciej ^d   Mlynarski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF PALERMO   (Italy)

^c Regional Hospital   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Lipid subpopulations; MODY; Monogenic diabetes

Indexed keywords

GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HNF1A PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; BLOOD; CASE CONTROL STUDY; CHILD; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; YOUNG ADULT;

EID: 84905908783     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0567-1     Document Type: Article

References (35)

1. Rizzo M, Rizvi AA, Rini GB, Berneis K (2009) The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol 46:1-11. doi:10.1007/s00592-008- 0057-4
2. McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM, Ellard S, Owen KR, Malecki MT, Hattersley AT, Young IS (2012) Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta 413:927-932. doi:10.1016/j.cca.2012.02.005
3. Fendler W, Borowiec M, Antosik K, Szadkowska A, Deja G, Jarosz-Chobot P, Mysliwiec M, Wyka K, Pietrzak I, Skupien J, Malecki MT, Mlynarski W (2011) HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults. Clin Endocrinol (Oxf) 75:321-327. doi:10.1111/j.1365-2265.2011.04052.x
4. Borowiec M, Fendler W, Antosik K, Ciepiela A, Baranowska A, Hogendorf A, Mianowska B, Szadkowska A, Mlynarski W (2010) Optimization of monogenic diabetes screening programme-initial report on recruitment efficacy of the TEAM project. Pediatr Endocrinol Diabetes Metab 16:73-76
5. Borowiec M, Antosik K, Fendler W, Deja G, Jarosz-Chobot P, Mysliwiec M, Zmyslowska A, Malecki M, Szadkowska A, Mlynarski W (2012) Novel glucokinase mutations in patients with monogenic diabetes - clinical outline of GCK-MD and potential for founder effect in Slavic population. Clin Genet 81:278-283. doi:10.1111/j.1399-0004.2011.01656.x
6. Borowiec M, Fendler W, Antosik K, Baranowska A, Gnys P, Zmyslowska A, Malecki M, Mlynarski W (2012) Doubling the referral rate of monogenic diabetes through a nationwide information campaign - update on glucokinase gene mutations in a Polish cohort. Clin Genet 82:587-590. doi:10.1111/j.1399-0004.2011.01803.x
7. Szadkowska A, Pietrzak I, Mianowska B, Bodalska-Lipinska J, Keenan HA, Toporowska-Kowalska E, Mlynarski W, Bodalski J (2008) Insulin sensitivity in type 1 diabetic children and adolescents. Diabet Med 25:282-288. doi:10.1111/j.1464-5491.2007.02357.x (Pubitemid 351322697)
8. Skupien J, Gorczynska-Kosiorz S, Klupa T, Cyganek K, Wanic K, Borowiec M, Sieradzki J, Malecki MT (2008) Molecular background and clinical characteristics of HNF1A MODY in a Polish population. Diabetes Metab 34:524-528. doi:10.1016/j.diabet.2008.05.004
9. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem 47:266-274 (Pubitemid 32142925)
10. Oravec S, Dostal E, Dukat A, Gavornik P, Kucera M, Gruber K (2011) HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 32:502-509. doi:NEL320411A13
11. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, Mikhailidis DP, Elisaf M (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23:1169-1176. doi:10.1185/030079907X188062 (Pubitemid 46799601)
12. Tsuzaki K, Kotani K, Sano Y, Fujiwara S, Gazi IF, Elisaf M, Sakane N (2012) The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism 61:17-21. doi:10.1016/j.metabol.2011.06.021
13. Keselman HJ, Cribbie RA, Holland B (2004) Pairwise multiple comparison test procedures: an update for clinical child and adolescent psychologists. J Clin Child Adolesc Psychol 33:623-645. doi:10.1207/s15374424jccp3303-19 (Pubitemid 39210004)
14. Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, Passa P, Deschamps I, Robert JJ, Weber IT, Marotta D, Pilkis SJ, Lipkind GM, Bell GI, Froguel P (1997) Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 40:217-224. doi:10.1007/s001250050666 (Pubitemid 27060296)
15. Borowiec M, Fendler W, Dusatkova P, Antosik K, Pruhova S, Cinek O, Mysliwiec M, Jarosz-Chobot P, Malecki MT, Mlynarski W (2012) HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2). Diabet Med 29:1465-1469. doi:10.1111/j.1464-5491.2012.03671.x
16. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, Tewhey R, Rieder MJ, Hall J, Abecasis G, Tai ES, Welch C, Arnett DK, Lyssenko V, Lindholm E, Saxena R, de Bakker PI, Burtt N, Voight BF, Hirschhorn JN, Tucker KL, Hedner T, Tuomi T, Isomaa B, Eriksson KF, Taskinen MR, Wahlstrand B, Hughes TE, Parnell LD, Lai CQ, Berglund G, Peltonen L, Vartiainen E, Jousilahti P, Havulinna AS, Salomaa V, Nilsson P, Groop L, Altshuler D, Ordovas JM, Kathiresan S (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112-3121. doi:10.2337/db08-0516
17. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, Marz W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E (2011) "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 9:533-571. doi:BSP/CVP/EPub/0000164
18. Oravec S, Dostal E, Gruber K (2013) Lipoprotein Lp(a) in lipoprotein spectrum indentified by Lipoprint LDL system. Neuro Endocrinol Lett 34:309-313
19. Evans K, Mitcheson J, Laker MF (1995) Effect of storage at 4 degrees C and -20 degrees C on lipid, lipoprotein, and apolipoprotein concentrations. Clin Chem 41:392-396
20. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K (2009) Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naive patients with early rheumatoid arthritis. Atherosclerosis 207:502-506. doi:10.1016/j.atherosclerosis.2009.07.015
21. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D, Szopa M, Tjora E, James TJ, Kokko P, Loiseleur F, Andersson E, Gaget S, Isomaa B, Nowak N, Raeder H, Stanik J, Njolstad PR, Malecki MT, Klimes I, Groop L, Pedersen O, Froguel P, McCarthy MI, Gloyn AL, Owen KR (2011) A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54:2801-2810. doi:10.1007/s00125-011-2261-y
22. Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, Malecki MT, McCarthy MI, Stoffel M, Owen KR (2013) Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes. Diabet Med 30:246-250. doi:10.1111/dme.12066
23. Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, Hattersley AT, Shields BM (2013) Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One 8:e65326. doi:10.1371/journal.pone.0065326
24. Calcaterra V, Martinetti M, Salina A, Aloi C, Larizza D (2012) The coexistence of type 1 diabetes, MODY2 and metabolic syndrome in a young girl. Acta Diabetol 49:401-404. doi:10.1007/s00592-011-0300-2
25. Spegel P, Ekholm E, Tuomi T, Groop L, Mulder H, Filipsson K (2013) Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2). Diabetes 62:653-661. doi:10.2337/db12-0827
26. Tinto N, Zagari A, Capuano M, De Simone A, Capobianco V, Daniele G, Giugliano M, Spadaro R, Franzese A, Sacchetti L (2008) Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from South Italy. PLoS One 3:e1870. doi:10.1371/journal.pone.0001870
27. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, Hattersley AT (2014) Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 57:54-56. doi:10.1007/s00125-013-3075-x
28. Ensign W, Hill N, Heward CB (2006) Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52:1722-1727. doi:10.1373/clinchem.2005.059949 (Pubitemid 44330706)
29. Superko HR, Pendyala L, Williams PT, Momary KM, King SB 3rd, Garrett BC (2012) High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 6:496-523. doi:10.1016/j.jacl.2012.03.001
30. Salem M, Moneir I, Adly AM, Esmat K (2011) Study of coronary artery calcification risk in Egyptian adolescents with type-1 diabetes. Acta Diabetol 48:41-53. doi:10.1007/s00592-010-0214-4
31. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Rewers M (2011) Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60:306-314. doi:10.2337/db10-0328
32. Bausserman LL, Saritelli AL, Milosavljevic D (1994) High-density lipoprotein subfractions measured in stored serum. Clin Chem 40:1713-1716 (Pubitemid 24273093)
33. Nanjee MN, Miller NE (1990) Evaluation of long-term frozen storage of plasma for measurement of high-density lipoprotein and its subfractions by precipitation. Clin Chem 36:783-788 (Pubitemid 20172872)
34. Kozian DH, Barthel A, Cousin E, Brunnhofer R, Anderka O, Marz W, Bohm B, Winkelmann B, Bornstein SR, Schmoll D (2010) Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 42:502-506. doi:10.1055/s-0030-1249637
35. De Ceuninck F, Kargar C, Charton Y, Goldstein S, Perron-Sierra F, Ilic C, Caliez A, Rolin JO, Sadlo M, Harley E, Vinson C, Ktorza A (2013) S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice. Br J Pharmacol 169:999-1010. doi:10.1111/bph.12172